Long-term outcome of patients with acquired primary idiopathic pure red cell aplasia receiving cyclosporine A. a nationwide cohort study in Japan for the PRCA Collaborative Study Group

Haematologica

Volumn 92, Issue 8, 2007, Pages 1021-1028

  Sawada, Ken Ichi ^a   Hirokawa, Makoto ^a   Fujishima, Naohito ^a   Teramura, Masanao ^b   Bessho, Masami ^c   Dan, Kazuo ^d   Tsurumi, Hisashi ^e   Nakao, Shinji ^f   Urabe, Akio ^g   Omine, Mitsuhiro ^h   Ozawa, Keiya ⁱ  

^a AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

^d NIPPON MEDICAL SCHOOL   (Japan)

^e GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^g Kanto Teishin Hospital   (Japan)

^h SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

ⁱ JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Cyclosporine A; Maintenance therapy; Pure red cell aplasia; Relapse free survival

Indexed keywords

ANABOLIC AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; METHYLPREDNISOLONE; PREDNISOLONE; THYMOCYTE ANTIBODY; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; COHORT ANALYSIS; CORRELATION ANALYSIS; DEATH; DISEASE FREE SURVIVAL; HEALTH SURVEY; HUMAN; JAPAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PURE RED CELL ANEMIA; RELAPSE; REMISSION; TREATMENT DURATION; ADOLESCENT; ADULT; AGED; AUTOIMMUNE DISEASE; BLOOD DISEASE; DRUG SCREENING; FEMALE; FOLLOW UP; MALE; MIDDLE AGED; MORTALITY; MYELODYSPLASTIC SYNDROME; PRELEUKEMIA; RECURRENT DISEASE; SALVAGE THERAPY; SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; AUTOIMMUNE DISEASES; COHORT STUDIES; CYCLOPHOSPHAMIDE; CYCLOSPORINE; DISEASE-FREE SURVIVAL; DRUG EVALUATION; FEMALE; FOLLOW-UP STUDIES; HEALTH SURVEYS; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JAPAN; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PRELEUKEMIA; RECURRENCE; RED-CELL APLASIA, PURE; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 35748941382     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11192     Document Type: Article

References (22)

1. Dessypris EN. Pure red cell aplasia. Johns Hopkins Univ Press, 1988; Baltimore, USA.
2. th ed, Lippincott Williams & Wilkins, Philadelphia, USA. 2004. p. 1421-7,
3. Raghavachar A. Pure red cell aplasia: review of treatment and proposal for a treatment strategy. Blut 1990;61:47-51.
4. Marmont AM. Therapy of pure red cell aplasia. Semin Hematol 1991; 28:285-97.
5. Fisch P, Handgretinger R, Schaefer HE. Pure red cell aplasia. Br J Haematol 2000;111:1010-22.
6. Lacy MQ, Kurtin PJ, Tefferi A. Pure red cell aplasia: association with large granular lymphocyte leukemia ana the prognostic value of cytogenetic abnormalities. Blood 1996; 87:3000-6.
7. Mamiya S, Itoh T, Miura AB. Acquired pure red cell aplasia in Japan. Eur J Haematol 1997;59:199-205.
8. Zecca M, Stefano P, Nobili B, Locatelli F. Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. Blood 2001;97:3995-7.
9. Ghazal H. Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia. Blood 2002;99:1092-4.
10. Ru X, Liebman HA. Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H). Br J Haematol 2003;123:278-81.
11. Clark AD, Dessypris EN, Krantz SB. Studies on pure red cell aplasia. XI. Results of immunosuppressive treatment of 37 patients. Blood 1984;63:277-86.
12. Totterman TH, Nisell J, Killander A, Gahrton G, Lonqvist B. Successful treatment of pure red cell aplasia with cyclosporine. Lancet 1984;2:694.
13. Go RS, Li CY, Tefferi A, Phyliky RL. Acquired pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes. Blood 2001;98:483-5.
14. Oshimi K, Yamada O, Kaneko T, Nishinarita S, Iizuka Y, Urabe A, et al. Laboratory findings and clinical courses of 33 patients with granular lymphocyte-proliferative disorders. Leukemia 1993;7:782-8.
15. Means RT Jr, Dessypris EN, Krantz SB. Treatment of refractory pure red cell aplasia with cyclosporine A: disappearance of IgG inhibitor associated with clinical response. Br J Haematol 1991;78:114-9.
16. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc 1996;71:5-13.
17. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004;4:222-30.
18. Bustami RT, Ojo AO, Wolfe RA, Merion RM, Bennett WM, McDiarmid SV, et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 2004: 4:87-93
19. Pendes S, Ginsburg E, Singh AK. Strategies for preservation of ovarian and testicular function after immunosuppression. Am J Kidney Dis 2004;43:772-81.
20. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006;108:2509-19.
21. Cattran DC, Greenwood C, Ritchie S, Bernstein K, Churchill DN, Clark WF, et al. A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian Glomerulonephritis Study Group. Kidney Int 1995;47:1130-5.
22. Bouchard MJ, Puro RJ, Wang L, Schneider RJ. Activation and inhibition of cellular calcium and tyrosine kinase signaling pathways identify targets of the HBx protein involved in hepatitis B virus replication. J Virol 2003;77:7713-9.